What is Tandem Diabetes Care's SG&A?

Tandem Diabetes Care (TNDM) reported SG&A of $108.19M in Q1 2026.

How has Tandem Diabetes Care's SG&A changed year-over-year?

Tandem Diabetes Care's SG&A decreased by 5.0% year-over-year, from $113.85M to $108.19M.

What is the long-term trend for Tandem Diabetes Care's SG&A?

Over 4 years (2021 to 2025), Tandem Diabetes Care's SG&A has grown at a 14.2% compound annual growth rate (CAGR), from $261.51M to $444.99M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Tandem Diabetes Care TNDM SG&A

SG&A at other companies

InsuletPODD

$317.2M+21.7%

MedtronicMDT

$3.06B+12.4%

MannkindMNKD

$54.09M+116%

AbbottABT

$3.74B+22.2%

OmnicellOMCL

$101.99M0.0%

ICU MedicalICUI

$154.57M-1.7%

Other financials

Income statement

See full

Revenue$247.2M+5.5%

Gross profit$136.8M+15.5%

Operating income-$17.4M+85.6%

Net income-$20.4M+84.4%

EPS (diluted)-$0.30+84.8%

Balance sheet

See full

Cash & equivalents$179.3M+235%

Total debt$734.7M+49.0%

Total equity$132.4M-14.7%

Total assets$1.2B+25.1%

Cash flow

See full

Operating cash flow$11.1M+160%

CapEx$6.3M+111%

Free cash flow$4.8M+123%

Valuation

See full

Market cap$1.03B-19.8%

Enterprise value$1.58B-8.5%

P/S1×-0.3×

Profitability

See full

Gross margin54.9%+2.7pp

Operating margin-8.2%-2.9pp

Net margin-9.2%-3.1pp

FCF margin-0.8%-0.4pp

Returns & leverage

See full

Return on equity-65.7%-14.7pp

Debt / equity5.5×+2.4×

Current ratio3.6×+1.3×

Where this comes from

Reported directly by Tandem Diabetes Care in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tandem Diabetes Care's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tandem Diabetes Care's SG&A?: Tandem Diabetes Care (TNDM) reported SG&A of $108.19M in Q1 2026.
How has Tandem Diabetes Care's SG&A changed year-over-year?: Tandem Diabetes Care's SG&A decreased by 5.0% year-over-year, from $113.85M to $108.19M.
What is the long-term trend for Tandem Diabetes Care's SG&A?: Over 4 years (2021 to 2025), Tandem Diabetes Care's SG&A has grown at a 14.2% compound annual growth rate (CAGR), from $261.51M to $444.99M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.